Source: Times of India

video

NEW DELHI: With hydroxychloroquine regaining its credibility after WHO restarted its trials and the authors of a Lancet study slamming it falling into controversy, India’s Covid-19 diplomacy, of which supply of HCQ to dozens of countries was an important part, could gain ground again.

A global controversy regarding the drug and its efficacy as a prophylactic against Covid-19 or even as a treatment began with studies in respectable journals, the Lancet and the New England Journal of Medicine, questioning its use and hinting it could increase mortality rates among patients with a heart condition.

The drug was battling a political controversy with US President not only advocating its use but also announcing that he was taking it. As with many Trump announcements, the declaration sparked a war of words with some US experts warning against its use in Covid-19 treatment protocol though the FDA has defined its use in hospital conditions.

India has remained steadfast in recommending its use as a preventive tool for frontline those in direct contact with Covid-19 patients.

HCQ and paracetamol was supplied to over 133 countries, both as grant as well as on commercial basis, as of mid-May. This includes 446 million HCQ tablets and 1.54 billion paracetamol tablets. So far, 76 countries have been provided with HCQ tablets as grant assistance by India. If HCQ had fallen into disrepute, much of this goodwill would have lost its sheen. India has focused its attention on the immediate neighbourhood which was the first priority, before spreading out its aid to Gulf countries, some Asean countries, African and Latin American countries and central Asia.

For instance, India has earmarked 5 million HCQ tablets for 28 LAC countries and 100,000 each for 19 African countries, as per official sources. By May, India had ramped up production of HCQ production capacity to 300 million tablets per month.

Related: Despite WHO’s Warning, India Continues Use of Hydroxychloroquine as Prevention Measure

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »